US Patent

US7112592 — Azabicyclic compounds, preparation thereof and use as medicines, in particular as antibacterial agents

Method of Use · Assigned to Aventis Pharma SA · Expires 2026-01-07 · 0y expired

Vulnerability score 78/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects new heterocyclic compounds and their salts, as well as a process for preparing them, for use as medicaments, particularly as antibacterial agents.

USPTO Abstract

The invention relates to new heterocyclic compounds of general formula (I), and their salts with a base or an acid: The invention also relates to a process for the preparation of these compounds as well as their use as medicaments, in particular as anti-bacterial agents.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-4147
U-2508

Patent Metadata

Patent number
US7112592
Jurisdiction
US
Classification
Method of Use
Expires
2026-01-07
Drug substance claim
Yes
Drug product claim
Yes
Assignee
Aventis Pharma SA
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.